Key result
Cyclophosphamide treatment significantly decreased coxsackievirus B-3 uptake by peritoneal exudate cells at 72 hours compared to untreated mice, potentially worsening infection severity.
Why the study?
Does cyclophosphamide treatment alter the viral uptake of coxsackievirus B-3 by peritoneal exudate cells in adult mice?
Population
Peritoneal exudate cells (p.e.c.) of adult mice
Comparison
Cyclophosphamide treatment vs Normal untreated mice
Design
Preclinical
Authors
Loading...
Decreased uptake may worsen infection in this model; hypothesis-generating for coxsackievirus outcomes under immunosuppression, needs human validation.
Does cyclophosphamide treatment alter the viral uptake of coxsackievirus B-3 by peritoneal exudate cells in adult mice?
Cyclophosphamide treatment reduces viral uptake by peritoneal exudate cells at 72 hours, which may contribute to the severity of coxsackievirus B-3 infection in treated mice.
Kabiri et al. (1977) studied Coxsackievirus B-3 infection. Cyclophosphamide vs. Normal untreated mice was evaluated on Viral uptake by peritoneal exudate cells. Cyclophosphamide treatment significantly decreased coxsackievirus B-3 uptake by peritoneal exudate cells at 72 hours compared to untreated mice, potentially worsening infection severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: